Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions

PHASE2CompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

April 14, 2015

Primary Completion Date

May 26, 2016

Study Completion Date

May 26, 2016

Conditions
PTSD
Interventions
DRUG

TNX-102 SL

1x 2.8mg TNX-102 SL Sublingual tablet

Trial Locations (22)

11516

Neurobehavioral Research, Inc., Cedarhurst

30308

Atlanta Center For Medical Research, Atlanta

32025

Sarkis Clinical Trials, Lake City

32801

Clinical Neuroscience Solutions, Inc., Orlando

34748

Compass Research North, LLC, Leesburg

35404

Tuscaloosa VA Medical Center, Tuscaloosa

44106

University Hospitals Case Medical Center, Cleveland

45219

University of Cincinnati College of Medicine, Cincinnati

60640

Great Lakes Clinical Trials, Chicago

68526

Premier Psychiatric Research Institute, Inc., Lincoln

78229

Clinical Trials of Texas, San Antonio

85032

Noesis Pharma, Phoenix

89102

Altea Research, Las Vegas

90502

Cns, Inc., Torrance

91950

Synergy Clinical Research, National City

92103

CESAMH, San Diego

92251

Sun Valley Research Center, Imperial

92506

Excell Research, Inc, Oceanside

CITRIALS, Riverside

92868

Neuropsychiatric Research Center of Orange County, Orange

98007

Northwest Clinical Research Center, Bellevue

02740

Novex Clinical Research, New Bedford

All Listed Sponsors
lead

Tonix Pharmaceuticals, Inc.

INDUSTRY

NCT02421679 - Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions | Biotech Hunter | Biotech Hunter